Evidence map›Paper›PMID 36197469›Full record

ArticleActa neuropathologica2022

Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.

Fanny Roth, Jamila Dhiab, Alexis Boulinguiez, Hadidja-Rose Mouigni, Saskia Lassche, Elisa Negroni, Laura Muraine, Alix Marhic, Alison Oliver, Jeanne Lainé and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 4 countries.

Fanny Roth *Myology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Jamila Dhiab *Myology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Alexis Boulinguiez *Myology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Hadidja-Rose MouigniMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Saskia LasscheDepartment of Physiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Elisa NegroniMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Laura MuraineMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Alix MarhicMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Alison OliverMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Jeanne LainéMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Andrée RoucheMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Erin K O'FerrallDepartment of Neurology and Neurosurgery, McGill University, Montréal, Canada.
Baziel van EngelenDepartment of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
Coen OttenheijmDepartment of Physiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Hagar GreifBioBlast-Pharma Ltd., Tel-Aviv, Israel.
Sergiu BlumenDepartment of Neurology, Hadera and Rappaport Faculty of Medicine, Hillel Yaffe Medical Center, The Technion, 1 Efron Street, 31096, Haifa, Israel.
Jean Lacau St GuilyMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Sophie PerieMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Gillian Butler-BrowneMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Vincent MoulyMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France.
Capucine TrolletMyology Center for Research, U974, Sorbonne Université, INSERM, AIM, GH Pitie Salpetrière Bat Babinski, 47 bd de l'Hopital, 75013, Paris, France. capucine.trollet@upmc.fr.ORCID http://orcid.org/0000-0002-4838-3712
Inserm · FRAmsterdam University Medical Centers · NLBioBlast Pharma (Israel) · ILHillel Yaffe Medical Center · ILMontreal Neurological Institute and Hospital · CARadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a rare muscle disease characterized by an onset of weakness in the pharyngeal and eyelid muscles. The disease is caused by the extension of a polyalanine tract in the Poly(A) Binding Protein Nuclear 1 (PABPN1) protein leading to the formation of intranuclear inclusions or aggregates in the muscle of OPMD patients. Despite numerous studies stressing the deleterious role of nuclear inclusions in cellular and animal OPMD models, their exact contribution to human disease is still unclear. In this study, we used a large and unique collection of human muscle biopsy samples to perform an in-depth analysis of PABPN1 aggregates in relation to age, genotype and muscle status with the final aim to improve our understanding of OPMD physiopathology. Here we demonstrate that age and genotype influence PABPN1 aggregates: the percentage of myonuclei containing PABPN1 aggregates increases with age and the chaperone HSP70 co-localize more frequently with PABPN1 aggregates with a larger polyalanine tract. In addition to the previously described PRMT1 and HSP70 co-factors, we identified new components of PABPN1 aggregates including GRP78/BiP, RPL24 and p62. We also observed that myonuclei containing aggregates are larger than myonuclei without. When comparing two muscles from the same patient, a similar amount of aggregates is observed in different muscles, except for the pharyngeal muscle where fewer aggregates are observed. This could be due to the peculiar nature of this muscle which has a low level of PAPBN1 and contains regenerating fibers. To confirm the fate of PABPN1 aggregates in a regenerating muscle, we generated a xenograft model by transplanting human OPMD muscle biopsy samples into the hindlimb of an immunodeficient mouse. Xenografts from subjects with OPMD displayed regeneration of human myofibers and PABPN1 aggregates were rapidly present-although to a lower extent-after muscle fiber regeneration. Our data obtained on human OPMD samples add support to the dual non-exclusive models in OPMD combining toxic PABPN1 intranuclear inclusions together with PABPN1 loss of function which altogether result in this late-onset and muscle selective disease.

Indexed as

Muscular Dystrophy, OculopharyngealAnimalsDisease Models, AnimalHeterograftsHumansIntranuclear Inclusion BodiesMiceMolecular ChaperonesPoly(A)-Binding Protein IProtein-Arginine N-MethyltransferasesRepressor ProteinsMolecular ChaperonesPABPN1 protein, humanPoly(A)-Binding Protein IPRMT1 protein, humanProtein-Arginine N-MethyltransferasesRepressor ProteinsHuman biopsiesInclusionsLoss of functionNuclear aggregatesOPMDPABPN1Xenograft

Identifiers

PMID36197469
PMCPMC9637588
OpenAlexW4301595356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.